Evidence map›Paper›PMID 29949051›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2018

Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer.

Linus Angenendt, Jan-Henrik Mikesch, Dennis Görlich, Alina Busch, Irina Arnhold, Claudia Rudack, Wolfgang Hartmann, Eva Wardelmann, Wolfgang E Berdel, Markus Stenner and 2 more

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. The role of collagen in cancer: from bench to bedside.Journal of translational medicine · 2019
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Linus AngenendtDepartment of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. linus.angenendt@ukmuenster.de.ORCID http://orcid.org/0000-0003-2502-9910
Jan-Henrik MikeschDepartment of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Dennis GörlichInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Alina BuschDepartment of Internal Medicine II, University Hospital Eppendorf, Hamburg, Germany.
Irina ArnholdDepartment of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Claudia RudackDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Münster, Münster, Germany.
Wolfgang HartmannGerhard-Domagk-Institute of Pathology, University Hospital Münster, Albert Schweitzer Campus 1, 48149, Münster, Germany.
Eva WardelmannGerhard-Domagk-Institute of Pathology, University Hospital Münster, Albert Schweitzer Campus 1, 48149, Münster, Germany.
Wolfgang E BerdelDepartment of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Markus StennerDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Münster, Münster, Germany.
Christoph SchliemannDepartment of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Inga GrünewaldGerhard-Domagk-Institute of Pathology, University Hospital Münster, Albert Schweitzer Campus 1, 48149, Münster, Germany. inga.gruenewald@ukmuenster.de.
University Hospital Münster · DEUniversität Hamburg · DEUniversity of Münster · DE

Funding

DFG DFG EXC 1003IMF Münster SC111411IMF Münster SC211008IMF Münster SC221410
6 · The paper itself

Abstract

purposeCollagen Type VI (COLVI) is an extracellular matrix protein that is upregulated in various solid tumours during tumour progression and has been shown to stimulate proliferation, suppress apoptosis and promote invasion and metastasis. It has also been described as a mediator of chemotherapy resistance and as a therapeutic target in preclinical cancer models. Here, we aimed to analyse the prognostic role of COLVI in salivary gland cancer (SGC).

methodsStromal COLVI protein expression was assessed in primary SGC specimens of 91 patients using immunohistochemistry (IHC). The IHC expression patterns obtained were subsequently correlated with various survival and clinicopathological features, including Ki-67 and p53 expression.

resultsWe found that COLVI was expressed in all SGC specimens. High expression was found to be associated with features of malignancy such as high histologic grades, advanced and invasive T stages and metastatic lymph node involvement (p < 0.05 for all variables). COLVI expression was also found to correlate with both Ki-67 and p53 expression (p < 0.01). We found that high COLVI expression predicted a significantly inferior 5-year overall survival (38.3%, 55.1% and 93.8%; p = 0.002) and remained a significant predictor of prognosis in a multivariate Cox regression analysis (hazard ratio, 2.62; 95% confidence interval, 1.22-5.61; p = 0.013). In all low-risk subgroups COLVI expression identified patients with an adverse outcome. Patients receiving adjuvant radiotherapy had a poor survival when expressing high levels of COLVI.

conclusionsOur data indicate that stromal COLVI expression associates with key features of malignancy, represents a novel independent prognostic factor and may affect response to radiotherapy in SGC. Although our results warrant validation in an independent cohort, assessing stromal COLVI expression may be suitable for future diagnostic and therapeutic decision making in patients with SGC.

Indexed as

AdultAgedAged, 80 and overApoptosisCell ProliferationCollagen Type VIExtracellular Matrix ProteinsFemaleHumansMaleMiddle AgedMultivariate AnalysisParotid NeoplasmsPrognosisSalivary Gland NeoplasmsTissue Array AnalysisCollagen Type VIExtracellular Matrix ProteinsCollagen type VIParotid cancerPrognosisSalivary gland carcinomaTissue microarray

Identifiers

PMID29949051
PMCPMC12995206
OpenAlexW2807786018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.